New research suggests that a higher dose of semaglutide could lead to greater weight loss than the standard treatment. In two large international trials, patients taking a triple dose not only lost more weight but were also more likely to achieve major milestones like a 20% or 25% reduction in body weight. They also saw improvements in waist size, blood pressure, blood sugar, and cholesterol, pointing to wider health benefits beyond weight management.
The higher dose was generally well tolerated, with side effects mostly limited to mild gastrointestinal issues that eased over time. Some patients reported tingling or numbness, a signal researchers say requires further study. Importantly, serious health problems were no more common in the high-dose group than in those taking the standard dose.
Experts say these findings could reshape obesity treatment, especially for people who haven’t met their goals with lower doses. But they also caution that questions remain about long-term safety and whether such high doses are right for everyone. While promising, this approach is still under investigation, and regulators will need to weigh the potential benefits against the risks before broader approval.
